position of the US as a locus of innovation in pharmaceuticals has increased over the past decade compared to Europe. All in … European countries. As a whole, Europe is lagging behind in its ability to generate, organise, and sustain innovation processes … in pharmaceuticals: 1) The size and the structure of the biomedical education and research systems; 2) Some basic …

measures that are affecting demand for pharmaceuticals in all major markets. This Perspective considers the impact of the …

, which covers both elementary units (products) and classes (markets, firms) in a given industry (pharmaceuticals), covering …

distinction seems to emerge. On the one hand, systems that rely on market-based competition in pharmaceuticals promote a clear …

This report addresses two main topics, R&D and innovation data availability and reliability in Hungary, as well as …&D and innovation on micro-economic performance, either, although these three sets of data (R&D, innovation, and company …. Foreign-owned firms tend to be large, and thus the decisive share of BERD is performed by large enterprises. Pharmaceuticals …

of innovation along very short paths, also constrains firms continuously and can lead to a fast reversal of their …

the 1990s. This enabled us to characterise several features of the innovation process in pharmaceuticals, particularly the …